{
    "title": "Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11797247/Shionogi-sees-COVID-pill-reaping-2-billion-annual-sales-U-S-approval.html",
    "date": "2023-02-27",
    "keywords": [
        "covid",
        "approval",
        "drug",
        "teshirogi",
        "shionogi",
        "japan",
        "co",
        "covid19",
        "pill",
        "company",
        "inc",
        "month",
        "market",
        "study",
        "health",
        "government",
        "year",
        "tokyo",
        "feb",
        "ltd",
        "chief",
        "executive",
        "protease",
        "inhibitor",
        "pfizer",
        "merck",
        "emergency",
        "november",
        "making",
        "treatment",
        "ceo",
        "isao",
        "korea",
        "china",
        "suggest",
        "virus",
        "probability",
        "hypothesis",
        "interview",
        "microscope",
        "care",
        "system",
        "paxlovid",
        "risk",
        "analyst",
        "barker",
        "winter",
        "phase",
        "trial",
        "part",
        "institutes",
        "estimate",
        "specialist",
        "drugmaker",
        "hiv",
        "influenza",
        "research",
        "development",
        "budget",
        "coronavirus",
        "recombinant",
        "vaccine",
        "shot",
        "omicron",
        "variant",
        "version",
        "plc",
        "companys",
        "investment",
        "concern",
        "pipeline",
        "public",
        "swift",
        "miyoung",
        "kim",
        "edwina",
        "gibbs"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}